Advanced search
Start date
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Prime-boost vaccination with recombinant protein and adenovirus-vector expressing Plasmodium vivax circumsporozoite protein (CSP) partially protects mice against Pb/Pv sporozoite challenge

Full text
Show less -
de Camargo, Tarsila Mendes [1] ; de Freitas, Elisangela Oliveira [1, 2] ; Gimenez, Alba Marina [3] ; Lima, Luciana Chagas [1] ; Caramico, Karina de Almeida [1] ; Francoso, Katia Sanches [1] ; Bruna-Romero, Oscar [4] ; Andolina, Chiara [5, 6] ; Nosten, Francois [5, 6] ; Renia, Laurent [7] ; Ertl, Hildegund C. J. [8] ; Nussenzweig, Ruth S. [9] ; Nussenzweig, Victor [9] ; Rodrigues, Mauricio M. [3] ; Reyes-Sandoval, Arturo [2] ; Soares, Irene S. [1]
Total Authors: 16
[1] Univ Sao Paulo, Sch Pharmaceut Sci, Dept Clin & Toxicol Anal, Sao Paulo, SP - Brazil
[2] Univ Oxford, Nuffield Dept Med, Jenner Inst, Henry Wellcome Bldg Mol Physiol, Roosevelt Dr, Oxford - England
[3] Univ Fed Sao Paulo, Dept Microbiol Immunol & Parasitol, Ctr Cellular & Mol Therapy, Sao Paulo, SP - Brazil
[4] Univ Fed Santa Catarina, Dept Microbiol & Immunol, Florianopolis, SC - Brazil
[5] Mahidol Univ, Fac Trop Med, Shoklo Malaria Res Unit, Mahidol Oxford Trop Med Res Unit, Mae Sot - Thailand
[6] Ctr Trop Med & Global Hlth, Nuffield Dept Med Res Bldg, Oxford - England
[7] Agcy Sci Technol & Res, Singapore Immunol Network, Biopolis, Singapore - Singapore
[8] Wistar Inst Anat & Biol, 3601 Spruce St, Philadelphia, PA 19104 - USA
[9] NYU, Sch Med, Dept Pathol, Michael Heidelberger Div, New York, NY - USA
Total Affiliations: 9
Document type: Journal article
Source: SCIENTIFIC REPORTS; v. 8, JAN 18 2018.
Web of Science Citations: 8

Vaccine development against Plasmodium vivax malaria lags behind that for Plasmodium falciparum. To narrow this gap, we administered recombinant antigens based on P. vivax circumsporozoite protein (CSP) to mice. We expressed in Pichia pastoris two chimeric proteins by merging the three central repeat regions of different CSP alleles (VK210, VK247, and P. vivax-like). The first construct (yPvCSP-All(FL)) contained the fused repeat regions flanked by N- and C-terminal regions. The second construct (yPvCSP-All(CT)) contained the fused repeat regions and the C-terminal domain, plus RI region. Mice were vaccinated with three doses of yPvCSP in adjuvants Poly (I:C) or Montanide ISA720. We also used replication-defective adenovirus vectors expressing CSP of human serotype 5 (AdHu5) and chimpanzee serotype 68 (AdC68) for priming mice which were subsequently boosted twice with yPvCSP proteins in Poly (I:C) adjuvant. Regardless of the regime used, immunized mice generated high IgG titres specific to all CSP alleles. After challenge with P. berghei ANKA transgenic parasites expressing Pb/PvVK210 or Pb/PvVK247 sporozoites, significant time delays for parasitemia were observed in all vaccinated mice. These vaccine formulations should be clinically tried for their potential as protective universal vaccine against P. vivax malaria. (AU)

FAPESP's process: 12/13032-5 - Generation and analysis of the immunogenicity of recombinant proteins based on the different allelic forms of the circumsporozoite antigen of Plasmodium vivax aiming at the development of a universal vaccine against malaria
Grantee:Irene da Silva Soares
Support Opportunities: Research Projects - Thematic Grants
FAPESP's process: 09/15099-7 - Immunogenic evaluation of recombinant proteins expressed in Pichia pastoris based on Plasmodium vivax antigens from different parasite stages
Grantee:Luciana Chagas de Lima
Support Opportunities: Scholarships in Brazil - Doctorate (Direct)
FAPESP's process: 14/18102-7 - Preclinical tests of recombinant adenovirus-based protein and vaccine formulations expressing the Plasmodium vivax circumsporozoite protein
Grantee:Alba Marina Gimenez
Support Opportunities: Scholarships in Brazil - Post-Doctorate